La chaîne d'options affiche les données clés des options sur actions de Holley à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Holley..

Holley (NYSE:HLLY) Stock, Chaîne d'Options

HOLLEY INC

Holley

Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.

Holley Inc

<a href="https://www.globenewswire.com/Tracker?data=H7tQ72YHj5SGVujfdKJYQ-z3niO-XQqqFsUoixlLf_JOseKdHKL3pwrpWiTFhnMWCKAf1J1xHMH10-QV7QbBfsf40qImmsYrKwbVVtpfcZ6_sBJkvUpbq6Wc7ZTF0bh_a2tchltodSqtocQlod-7lorrbbk5_W86UTA6HBDAx5mUoCZGeuDQa-l2NIwStLN1f7_I-cDCZaBbxaAqEM3Nbiu9Emh57OvycxbFarYzGb4=">Pharvaris</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), updated the guidance for the disclosure of topline data from the ongoing RAPIDe-3 pivotal Phase 3 study evaluating deucrictibant immediate-release (IR) capsule for the on-demand treatment of HAE attacks. Pharvaris anticipates announcing topline data from RAPIDe-3 in the fourth quarter of 2025 and, pending positive data, expects to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026.

News

PHVS

Pharvaris Anticipates Reporting Topline Data From Rapide-3 In Q4 Of 2025; Expects To Submit NDA With FDA In H1 Of 2026

ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) has <a href="https://www.benzinga.com/topic/semiconductors">experienced an 8% decline</a> in market value year-to-date, contrasting sharply with the PHLX Semiconductor Index&#8217;s 14% gain during the same period. 
This underperformance for ON Semiconductor stems from a failure to achieve topline growth over the past two quarters, reflecting weakened demand across its core business segments, including power solutions, analog, and sensing technologies. 
The softness in these areas is largely attributable to challenging conditions within the automotive and industrial markets. Despite these headwinds, the stock has recently seen a significant surge, gaining over 47% in the last three months and outperforming the index&#8217;s 34% rise, and it currently trades above its 50-day moving average of $47.56.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45237744/on-semiconductor-sees-green-shoots-in-industrial-auto-shift-as-analysts-stay-cautious" rel="noreferrer noopener">ON Semiconductor Powers Through Expectations, But Analysts Dial Down Targets On Margin Squeeze</a>
<h2 class="wp-block-heading">Recent Financial Performance and Strategic Shifts</h2>
Several factors appear to be driving this recent upward trend. On May 5, ON Semiconductor announced its <a href="https://www.benzinga.com/news/earnings/25/05/45196247/on-semiconductor-q1-earnings-beat-estimates-ceo-optimistic-on-design-wins-despite-margin-decline">fiscal first-quarter 2025</a> revenue declined 22.4% year-on-year to $1.45 billion, yet this still surpassed the analyst consensus estimate of $1.40 billion. 
While revenue from power solutions, analog, and sensing all decreased, the company&#8217;s adjusted gross margin saw a 590 basis point decline to 40.0%, indicating pricing pressures within the semiconductor industry. Looking ahead, ON Semiconductor anticipates second-quarter adjusted revenue to be between $1.40 billion and $1.45 billion, aligning with the analyst consensus of $1.42 billion.
Further contributing to investor sentiment, on February 26, the company unveiled a <a href="https://www.benzinga.com/media/25/02/43971798/on-semiconductor-focuses-on-ai-chip-growth-to-cut-2400-jobs-to-stay-competitive">comprehensive restructuring plan</a> aimed at cost reduction and margin improvement across all business units, including manufacturing. This initiative involves laying off approximately 2,400 employees, with an expected annual savings of $105 million to $115 million by 2025. 
CEO Hassane El-Khoury emphasized a strategic shift towards core operations, phasing out side projects to capitalize on the increasing demand driven by artificial intelligence. El-Khoury specifically highlighted the critical role of the company&#8217;s power chips in supporting large-scale GPU deployments, underscoring strong AI tailwinds. 
This strategic focus on AI and cost optimization seems to resonate with investors. Previously, on February 10, the company had reported a 15% <a href="https://www.benzinga.com/25/02/43592322/on-semiconductor-q4-earnings-q4-revenue-drops-15-weak-demand-in-auto-and-industrial-sectors-lower-utilization-hits-margins-ceo-warns-of-continued-challenges-in-2025">revenue decline</a> for fiscal fourth-quarter 2024, missing analyst estimates, and El-Khoury had expressed uncertainty regarding 2025, making the recent strategic announcements all the more impactful.
<h2 class="wp-block-heading">Macroeconomic Tailwinds and Headwinds</h2>
Macroeconomic indicators also play a role in ON Semiconductor&#8217;s outlook. The proposed &#8220;Big Beautiful Bill&#8221; in the U.S. <a href="https://www.benzinga.com/markets/tech/25/07/46324642/arm-rides-ai-boom-and-outperforming-market">could significantly benefit</a> the company by increasing the U.S. chip investment tax credit to 30% through 2026, thereby encouraging domestic manufacturing expansion. 
While the bill also ends the $7,500 EV tax credit after September 30, potentially leading automakers to raise EV prices and boost margins, this could, in turn, create more room for investment in advanced chips, thus stimulating demand for ON Semiconductor&#8217;s products. 
However, the escalating U.S.-China geopolitical tensions, particularly the tariff war, pose a significant risk, with potential retaliatory measures from China. Automakers are actively seeking alternative <a href="https://www.benzinga.com/markets/tech/25/06/45833037/auto-industry-struggles-as-supply-chain-issues-threaten-production-amid-chinas-export-curbs-on-rare-earth-minerals-report">rare-earth material</a> sources to circumvent China&#8217;s export restrictions, developing low-to-zero rare-earth motors, and strengthening local supply chains, a sentiment echoed by Tesla&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Elon Musk.
<h2 class="wp-block-heading">Analyst Outlook</h2>
Analyst perspectives on ON Semiconductor are varied. A consensus price target from twenty-eight analysts stands at $62.43. Recent ratings from KeyBanc, Citigroup, and UBS suggest an average target of $60, implying a potential upside of 3.70% for the stock. 
In April, Bank of America analysts Vivek Arya and Duksan Jang anticipated a <a href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst">first-quarter earnings</a> beat due to conservative outlooks and tariff-related demand shifts favoring U.S. chipmakers. They projected a mixed second quarter, with expanded guidance ranges reflecting lingering uncertainties from trade tensions and AI regulation. 
These analysts also cautioned that ON Semiconductor could face a 7%-9% sales hit under modest to dire tariff scenarios, potentially leading to EPS declines ranging from 12% to 30% and margin pressure of 150-500 basis points. They specifically noted that companies tied to consumer and auto segments, like ON Semiconductor, are more vulnerable than AI- and cloud-exposed peers such as Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) or Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>). 
Earlier in January, Needham&#8217;s N. Quinn Bolton <a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42958251/on-semi-sees-utilization-cuts-as-ev-demand-softens-analyst-warns">highlighted weak demand</a> in the company&#8217;s key automotive and industrial markets and ongoing inventory digestion, expecting management to reduce fab utilization below 65%, which would pressure adjusted gross margins in the first half of 2025. Despite this near-term weakness, Bolton identified ON Semiconductor as a strong candidate for a semiconductor cycle rebound. 
Price Action: ON stock is trading higher by 0.09% to $57.82 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46328802/dell-hpe-named-top-ai-server-plays-as-analyst-cites-14b-backlog" target="_blank" rel="noreferrer noopener">Dell, HPE Named Top AI Server Plays As Analyst Cites $14B Backlog</a></li>
</ul>
Image via Shutterstock

Movers

Tech

LRCX

NVDA

TSLA

What's Fueling ON Semiconductor's Recent Stock Surge?

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The FDA has set a target action date of April 28, 2026, for the application under the Prescription Drug User Fee Act (PDUFA).
"Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "The health needs of people living with HIV often change over time – whether it's managing comorbidities or navigating complex medication regimens. We believe DOR/ISL, if approved, will represent an important new complete regimen option designed to help meet their diverse needs."
The NDA is based on findings at Week 48 of two pivotal Phase 3 clinical trials (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05631093%3Fterm%3Dislatravir%26page%3D2%26rank%3D20&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=MK-8591A-051&amp;index=1&amp;md5=19f532bbd62d49517c24c6053c9e0533">MK-8591A-051</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05630755&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=MK-8591A-052&amp;index=2&amp;md5=f8766e7f07603170fb6d72efa6249476">MK-8591A-052</a>) where DOR/ISL was demonstrated to be non-inferior to baseline antiretroviral therapy (bART) in the open-label trial MK-8591A-051 and non-inferior to bictegravir/emtrictabine/tenofovir alafenamidei [BIC/FTC/TAF (50mg/200mg/25mg)] in the double-blind trial MK-8591A-052. Across both trials, the safety profile of DOR/ISL was generally comparable to comparator baseline antiretroviral regimens in trial MK-8591A-051 and BIC/FTC/TAF in trial MK-8591A-052. Data from these trials <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fmerck-announces-positive-data-from-phase-3-trials-that-show-the-investigational-once-daily-oral-two-drug-regimen-of-doravirine-islatravir-dor-isl-maintained-hiv-1-viral-suppression-at-week-48%2F%23%3A%7E%3Atext%3DMarch%252012%252C%25202025%252012%3A26%2520pm%2520ET.%2520DOR%2FISL%2Cto%2520comparator%2520antiretroviral%2520therapies%2520in%2520adults%2520with&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=were+presented&amp;index=3&amp;md5=3764ef6f22589fe8271e55c80e83d584">were presented</a> during the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

Government

Regulations

Merck's New Once-Daily HIV Pill Moves Closer to FDA Approval With April 2026 Decision Date

<ul>
<li>XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR)</li>
</ul>
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI&#xAE; (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis.
For patients treated with XTANDI plus leuprolide versus placebo plus leuprolide, EMBARK met the key secondary endpoint with a statistically significant and clinically meaningful improvement in OS. Results also showed a favorable trend towards improved OS for patients treated with XTANDI monotherapy versus placebo plus leuprolide, however the difference did not reach statistical significance. No new safety signals were observed in the analysis, and the safety results were consistent with the demonstrated safety profile of XTANDI.
XTANDI is currently approved in more than 80 countries, including in the United States, European Union, and Japan. Detailed OS results from EMBARK will be presented at a future medical meeting.
 &nbsp;

Pfizer And Astellas Pharma Report Topline Results From OS Analysis From Phase 3 EMBARK Study Evaluating XTANDI, In Combination With Leuprolide And As Monotherapy, In Men With nmHSPC With High Risk BCR

Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate of $0.90 by 54.65 percent. This is a 58.59 percent decrease over earnings of $0.99 per share from the same period last year. The company reported quarterly sales of $371.655 million which missed the analyst consensus estimate of $398.205 million by 6.67 percent. This is a 10.84 percent decrease over sales of $416.847 million the same period last year.

Earnings

Earnings Misses

HELE

Helen Of Troy Q1 Adj. EPS $0.41 Misses $0.90 Estimate, Sales $371.655M Miss $398.205M Estimate

Billionaire investor Ray Dalio warned on Wednesday that President Donald Trump's latest round of tariffs could deepen "stagflation" and may never deliver on promises to revive U.S. factory floors.
What Happened: "The tariffs are being put into place as a symptom of things that are changing that will be there anyway," the Bridgewater Associates founder said in a video on X.
Dalio said the White House hopes levies will raise revenue and "develop manufacturing, which the United States needs both for employment reasons and security reasons." But he cast doubt on that outcome. "There is a belief that tariffs will bring manufacturing back to the United States, I am uncertain of that."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I've gotten a lot of questions on the recent Trump tariffs and their impact on the global economy. There is a belief that tariffs will bring manufacturing back to the United States, I am uncertain of that. You can learn more about why, and what the current big debt cycle the… <a href="https://t.co/GRlP1kiAOG">pic.twitter.com/GRlP1kiAOG</a>
&mdash; Ray Dalio (@RayDalio) <a href="https://twitter.com/RayDalio/status/1942969885924925615?ref_src=twsrc%5Etfw">July 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The hedge-fund manager argued the world is shifting from decades of free-flowing capital and goods to "a more controlled world" where production is no longer done by the most efficient producer. "That creates less efficiency in the goods and services markets … and in the capital markets," he said, adding the result is "higher inflation and slower growth — more stagflation."
See also: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/07/46338091/dave-ramsey-tells-debt-laden-28-year-old-to-skip-courthouse-wedding-youll-tell-this-story-forever">Dave Ramsey Tells Debt-Laden 28-Year-Old To Skip Courthouse Wedding: &#8216;You&#8217;ll Tell This Story&#8217; Forever</a>
Why It Matters: Dalio's view echoes recent <a href="https://www.jpmorgan.com/insights/global-research/current-events/us-tariffs">forecasts</a> from J.P. Morgan and the OECD showing tariff-driven supply shocks shaving more than a point off <a href="https://www.oecd.org/en/about/news/press-releases/2025/06/global-economic-outlook-shifts-as-trade-policy-uncertainty-weakens-growth.html">global growth</a> next year. 
Trump's "reciprocal tariffs," which could reach 70% on some imports, are already rattling markets. Investors fear a replay of 2018's trade war, analysts <a href="https://www.theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a&amp;dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fbusiness%2Fmarkets%2Ftrumps-tariff-gambit-puts-investors-on-edge-as-deadline-looms%2Fnews-story%2Ff6f04a89069fe2b1aabc5080bafabacc&amp;memtype=anonymous&amp;mode=premium&amp;v21=GROUPB-Segment-2-NOSCORE&amp;V21spcbehaviour=append">told</a> The Australian. Harvard economists estimate the April round alone could trim U.S. GDP by <a href="https://hbr.org/2025/04/understanding-the-global-macroeconomic-impacts-of-trumps-tariffs">1.4 percentage points</a> in 2025.
Dalio has been sounding alarms for months, telling his X followers that <a href="https://www.benzinga.com/personal-finance/25/05/45249352/ray-dalio-says-its-too-late-to-escape-tariff-damage-worries-u-s-will-be-bypassed">tariffs are "too late"</a> to fix de-globalization and risk leaving the U.S. "bypassed by the rest of the world." He&#8217;s also pointed out that the ballooning federal debt plus higher import costs will trigger "<a href="https://www.benzinga.com/markets/guidance/25/07/46266299/ray-dalio-forecasts-big-painful-disruptions-as-us-national-debt-set-to-swell-over-next-decade">big, painful disruptions</a>."
Trump argues import taxes will bankroll domestic tax cuts and force trading partners to negotiate. Yet critics say higher prices for inputs like steel already threaten U.S. exporters. Dalio called the policy shift "theoretical" and said whether it truly boosts American factories "is still a question mark."
Read next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46337754/jim-cramer-says-a-tax-provision-in-trumps-one-big-beautiful-bill-could-gut-professional-gambling-heres-why-draftkings-fanduel-dont-mind">Jim Cramer Says A Tax Provision In Trump&#8217;s &#8216;One Big, Beautiful Bill&#8217; Could Gut Professional Gambling: Here&#8217;s Why DraftKings, FanDuel Don&#8217;t Mind</a></li>
</ul>
Image via Shutterstock

Economics

General

Ray Dalio Says Trump's Tariffs Are 'Theoretical,' Warns They May Not Bring Manufacturing Back To US

Wolfe Research analyst Steven Chubak upgrades Piper Sandler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>) from Peer Perform to Outperform and announces $339 price target.

Upgrades

Price Target

Analyst Ratings

PIPR

Wolfe Research Upgrades Piper Sandler to Outperform, Announces $339 Price Target

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">FY 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings Per Share</td>
<td colspan="1" rowspan="1">$5.25 - $6.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow ($B)</td>
<td colspan="1" rowspan="1">$3 - $4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Leverage2</td>
<td colspan="1" rowspan="1">Less than 2.5x</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Delta Air Lines Restores Its FY2025 Guidance: Sees Adj EPS $5.25-$6.25 vs $5.42 Est; Sees Free Cash Flow Of $3B-$4B

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) is looking for Q3 Adj EPS of $1.25-$1.75 vs $1.34 analyst estimate..

Delta Air Lines Sees Q3 Adj EPS $1.25-$1.75 vs $1.34 Est; Revenue Expected To Increase 0%-4% YoY

HC Wainwright &amp; Co. analyst Sean Lee maintains Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) with a Buy and raises the price target from $2 to $13.

KZIA

HC Wainwright & Co. Maintains Buy on Kazia Therapeutics, Raises Price Target to $13

Trilogy Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TMQ#AMEX">TMQ</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year.

Trilogy Metals Q2 EPS $(0.01), Inline

HC Wainwright &amp; Co. analyst Mike Colonnese downgrades Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from Buy to Sell and lowers the price target from $305 to $300.

Downgrades

COIN

HC Wainwright & Co. Downgrades Coinbase Global to Sell, Lowers Price Target to $300

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) reported quarterly earnings of $2.10 per share which beat the analyst consensus estimate of $2.05 by 2.49 percent. This is a 11.02 percent decrease over earnings of $2.36 per share from the same period last year. The company reported quarterly sales of $16.65 billion which beat the analyst consensus estimate of $15.45 billion by 7.76 percent. This is a 0.06 percent decrease over sales of $16.66 billion the same period last year.

Earnings Beats

Delta Air Lines Q2 Adj. EPS $2.10 Beats $2.05 Estimate, Sales $16.65B Beat $15.45B Estimate

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Americas Gold And Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/USAS#AMEX">USAS</a>) with a Buy and raises the price target from $1 to $1.3.

USAS

HC Wainwright & Co. Maintains Buy on Americas Gold And Silver, Raises Price Target to $1.3

U.S. stock futures declined on Thursday after ending higher on Wednesday. Futures of major benchmark indices were trading lower.
President Donald Trump imposed<a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46334793/trump-sends-lula-a-letter-imposing-50-tariffs-calls-bolsonaro-trial-a-witch-hunt-brazils-president-hits-back-will-not-accept-any-form-of-tutelage"> 50% tariffs on Brazil</a>, escalating the trade tensions between the two nations. This was followed by a slew of letters posted on his Truth Social account to Japan, South Korea, and other countries, with a deadline of making a deal by Aug. 1.
Trump also urged the Federal Reserve to cut interest rates by 3%, while <a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">June&#8217;s Fed minutes</a> were awash with words &#8220;uncertain&#8221; and &#8220;uncertainty,&#8221; over the tariffs.
The 10-year Treasury bond yielded 4.35% and the two-year bond was at 3.85%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool&#8217;s</a> projections show markets pricing a 93.3% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.23%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.17%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.16%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.15%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Thursday. The SPY was down 0.13% at $623.24, while the QQQ declined 0.086% to $555.77, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Information technology, utilities, and communication services stocks led the gains on Wednesday, driving U.S. stocks higher.
Investors largely overlooked fresh trade uncertainty, encouraged by the White House&#8217;s delay of new tariffs to Aug. 1st and renewed hopes for negotiations.
In contrast, energy and consumer staples stocks bucked the broader market trend, ending the session in the red.
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) once again dominated headlines, reaching a staggering <a href="https://www.benzinga.com/markets/market-summary/25/07/46328569/wall-street-today-tariffs-nvidia-4-trillion">$4 trillion market capitalization</a> and cementing its position as the world&#8217;s most valuable company. It plans to introduce a new AI chip specifically for the Chinese market as early as September.
On the economic data front, U.S. wholesale inventories saw a 0.3% month-over-month decline in May, falling to $905.5 billion, which was consistent with preliminary estimates and followed a 0.1% increase in the prior month.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.94%</td>
<td>20,611.34</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.61%</td>
<td>6,263.26</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.49%</td>
<td>44,458.30</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.07%</td>
<td>2,252.49</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
The senior global market strategist at Wells Fargo, Scott Wren, highlighted that the resurfaced tariff negotiations after a 90-day pause have again started to impact global stock and bond markets.
He said that &#8220;Some potentially serious trade frictions were just around the corner, ready to rear their ugly heads and impact global stock and bond markets.&#8221;
Wren highlighted that the first 90-day pause of largely reciprocal tariffs with a number of important trading partners was due to expire today, July 9. But as the financial markets woke up and got ready to go on Monday morning, the headlines hit the newswires that the pause was being pushed back to Aug. 1, and letters were going out to various trading partners encouraging them to come to an agreement with the U.S. by this new date.
&#8220;The upcoming expiration of the 90-day tariff pause on Aug. 12 with China are just a big reminder that we are still in the early stages of hammering out what U.S. trade relationships with our largest global trade partners will be,&#8221; he said.
Granted, the magnitude of implementation has been uneven and inconsistent in recent months, Wren said that &#8220;U.S. consumers have yet to see the full effect of tariffs at this point.&#8221;
&#8220;Consumers are in many cases buying goods that were inventoried by sellers prior to the application of tariffs. Once those inventories are depleted and are replaced with goods that are subject to tariffs, we would expect to see goods inflation increase into the end of this year and in the early months of 2026,&#8221; he said.
Wren added that &#8220;Rising inflation is likely to increase market worries as market consensus calls for two rate cuts in 2025.&#8221;
Meanwhile, talking about inflation, Louis Navellier of Navellier &amp; Associates stated that &#8220;I am expecting favorable inflation reports and for retail sales to have picked up a bit from May's slow pace.&#8221;
&#8220;Economic activity appears to be picking up, so both business and consumer sentiment should be rising,&#8221; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul class="wp-block-list">
<li>Initial jobless claims data for the week ended July 5 will all be out by 8:30 a.m. ET.</li>
<li>St Louis Fed President Alberto Musalem will speak at 10:00 a.m., and San Francisco Fed President Mary Daly will speak at 2:30 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rose 0.71% in premarket on Thursday after scaling a record market capitalization of over $4 trillion on Wednesday.</li>
<li>WK Kellogg Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) zoomed 52.86% on a report that Ferrero is nearing an agreement to buy the breakfast food company for about $3 billion.</li>
<li>Klotho Neurosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) surged 54.74% as the company was granted FDA Orphan Drug designation for KLTO-202 for the treatment of amyotrophic lateral sclerosis.</li>
<li>Creative Medical Technology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) tumbled 27% as it received a notice of allowance for a U.S. patent titled "Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells."</li>
<li>Methode Electronics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) dropped 14.29% after the company reported a fourth-quarter adjusted EPS miss.</li>
<li>AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) was 0.60% higher after posting better-than-expected earnings for its first quarter, while sales missed estimates. The company raised its FY2026 adjusted EPS guidance from $5.50-$6.10 to $5.75-$6.25.</li>
<li>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) was up 0.53% after it agreed to sell its infant and specialty food business in Italy to NewPrinces S.p.A.</li>
<li>Conagra Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) was up 0.79% as analysts expect it to report earnings of 58 cents per share on revenue of $2.83 billion before the opening bell.</li>
<li>Delta Air Lines Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) was 0.24% lower as it is expected to report earnings before the market opens. Analysts estimate earnings of $2.05 per share on revenue of $15.45 billion.</li>
<li>Helen of Troy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) advanced 1.29% as analysts expect it to report earnings of 90 cents per share on revenue of $398.20 million before the opening bell.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.53% to hover around $68.01 per barrel.
Gold Spot US Dollar rose 0.35% to hover around $3,325.28 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.16% at the 97.3950 level.
Asian markets ended mostly higher on Thursday, except India's S&amp;P BSE Sensex and Japan's Nikkei 225 indices. Meanwhile, South Korea's Kospi, Hong Kong's Hang Seng, Australia's ASX 200, and China&#8217;s CSI 300 indices rose. European markets were higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Photo courtesy: godongphoto / Shutterstock.com

Equities

CELZ

KLTO

US Stocks Likely To Open Lower A Day After Nasdaq Hits Record High: Nvidia, Kellogg, Klotho In Focus

HC Wainwright &amp; Co. analyst Brandon Folkes initiates coverage on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy rating and announces Price Target of $84.

Initiation

ANIP

HC Wainwright & Co. Initiates Coverage On ANI Pharmaceuticals with Buy Rating, Announces Price Target of $84

Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) has announced a <a target="_blank" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V455-7716.pdf" rel="noreferrer noopener">recall</a> of more than 850,000 vehicles in the U.S. due to a faulty fuel system component that may cause engines to stall while driving. The recall affects 11 models, including the Lincoln Navigator, Ford F-150, Explorer, Mustang, and various Super Duty trucks manufactured between July 2021 and July 2022.
The issue stems from a low-pressure fuel pump in the fuel delivery module, which can fail due to internal contamination and tight component clearances. This failure can lead to a sudden loss of fuel pressure and engine shutdown, especially under low fuel or high-temperature conditions. Drivers might notice signs such as rough idling, reduced power, or a check engine light before a failure occurs.
As of June, Ford had received nearly 1,900 warranty claims and over 80 related field and customer service reports. No accidents or injuries have been reported. The company is developing a fix and will begin mailing notices to vehicle owners in mid-July.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/07/46291379/nhtsa-launches-probe-into-stellantis-owned-ram-pickup-truck-recall-after-reports-of-injuries" target="_blank" rel="noreferrer noopener">NHTSA Launches Probe Into Stellantis-Owned RAM Pickup Truck Recall After Reports Of Injuries</a>
The defective component was supplied by Phinia Inc., based in Chihuahua, Mexico. Ford linked the problem to changes made in the supplier&#8217;s manufacturing process, which increased the risk of fuel pump friction and vapor lock. An investigation into the issue began in 2022.
This latest action adds to Ford&#8217;s growing list of vehicle safety challenges. Just weeks ago, the automaker also initiated a recall of Lincoln Aviator SUVs due to an adhesive flaw, another sign of <a href="https://www.benzinga.com/markets/tech/25/06/46068633/ford-recalls-aviator-suvs-as-adhesive-issue-adds-to-automakers-mounting-recall-woes" target="_blank" rel="noreferrer noopener">mounting recall woes</a> at the company.
Last week, Ford Motor <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46213625/ford-sales-surge-14-2-in-q2-beating-market-estimates-but-ev-sales-decline-31" rel="noreferrer noopener">reported</a> its second-quarter U.S. sales rose 14.2% to 612,095 vehicles, led by strong F-Series pickup demand. The company sold 222,459 F-Series trucks, up 11.5% year over year, and 156,509 electrified vehicles year to date, a 14.7% increase. EV sales declined 31.4% from a year ago to 16,438 units.
Related ETFs: SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), Global X Autonomous &amp; Electric Vehicles ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>).
Price Action: At the last check on Thursday, F shares were trading lower by 0.085% to $11.82 premarket.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46337340/elon-musk-says-tesla-will-expand-robotaxi-services-to-san-francisco-bay-area-in-a-month-or-two" target="_blank" rel="noreferrer noopener">Elon Musk Says Tesla Will Expand Robotaxi Services To San Francisco Bay Area &#8216;In A Month Or Two&#8217;</a></li>
</ul>
Image Via Shutterstock

Large Cap

DRIV

Ford Recalls Over 850,000 Vehicles Due To Stalling Engines

Biotech

Health Care

Financing

Offerings

RYTM

Rhythm Pharmaceuticals Prices Its Upsized Public Offering Of 2.06M Shares At $85/Share, With Gross Proceeds Of Approximately $175M

HC Wainwright &amp; Co. analyst Emily Bodnar maintains RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) with a Buy and raises the price target from $6 to $27.

RAPT

HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $27

<ul>
<li>The new network will allow Cuenta Nómina customers to withdraw cash without fees at more than 740 new ATMs throughout Spain.</li>
<li>The expansion is the result of an alliance with NCR Atleos, a provider specializing in financial self-service solutions.</li>
</ul>

ING Continues Its Growth In Spain By Expanding Services For Its More Than 4.4M Customers, Through More Than 740 New NCR Atleos Terminals, Its Customers Of "Cuenta Nómina" Will Be Able To Withdraw Cash Without Fees

Legal

Press Releases

Alert to Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra LifeSciences Holdings Corporation (NASDAQ: IART); Outset Medical, Inc. (NASDAQ: OM); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Is Investigating Claims on Your Behalf

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

Comments

Holley

Holley (HLLY) Options

Holley (NYSE:HLLY) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL